Vaxart
Vaxart is a biotechnology company that specializes in the development of oral recombinant vaccines. The company's proprietary technology platform is a novel approach to vaccine development, designed to allow for the oral administration of vaccines through a tablet, rather than by injection.
History[edit | edit source]
Vaxart was founded in 2004 with the goal of developing a new method of vaccine delivery that would improve the effectiveness and convenience of immunization. The company's initial focus was on the development of vaccines for influenza and norovirus, but it has since expanded its research and development efforts to include a range of other infectious diseases.
Technology[edit | edit source]
Vaxart's technology platform is based on the use of recombinant adenovirus vectors to deliver vaccine antigens to the immune system. This approach allows for the oral administration of vaccines, which has several potential advantages over traditional injection-based methods. These include improved patient compliance, the ability to stimulate a broader immune response, and the potential for mass distribution in the event of a pandemic.
Products[edit | edit source]
Vaxart's product pipeline includes vaccines for a number of infectious diseases, including influenza, norovirus, respiratory syncytial virus (RSV), and coronavirus disease 2019 (COVID-19). The company's influenza vaccine has completed Phase 2 clinical trials, while its norovirus and RSV vaccines are in preclinical development. In 2020, Vaxart initiated a Phase 1 clinical trial for its oral COVID-19 vaccine.
Financials[edit | edit source]
As a publicly traded company, Vaxart's financial performance is closely watched by investors. The company's revenue is primarily derived from collaboration agreements, licensing fees, and government grants. In recent years, Vaxart has received significant funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of its influenza and norovirus vaccines.
See also[edit | edit source]
References[edit | edit source]
External links[edit | edit source]
 |
This biotechnology company-related article is a stub. |
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
